PHASE-II STUDY OF DAILY ORAL MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN ADVANCED COLORECTAL-CANCER

被引：65
|
作者：
PLANTING, AST
STOTER, G
VERWEIJ, J
机构：
[1] Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, 3075 EA Rotterdam
来源：
EUROPEAN JOURNAL OF CANCER | 1993年 / 29A卷 / 04期
关键词：
D O I：
10.1016/S0959-8049(05)80142-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine). Most patients received 3 x 50 mg daily, while in 11 patients the dose could be escalated to 4 x 50 mg daily. Nausea and vomiting were the most frequent side-effects occurring in all but 3 patients, nephrotoxicity was observed in 11 patients. Leucocytosis was observed in 24 and thrombocytosis in 17 patients. 28 patients are evaluable for response. 1 patient obtained a partial response of liver metastases for a duration of 8 months. 3 patients had stable disease while 24 progressed during treatment. We conclude that miltefosine in this dose and schedule has limited activity in colorectal cancer.
引用
收藏
页码：518 / 519
页数：2
相关论文
共 50 条
  • [21] PHASE-II STUDY OF FTORAFUR IN PREVIOUSLY UNTREATED AND TREATED PATIENTS WITH ADVANCED COLORECTAL-CANCER
    SCHUTT, AJ
    HAHN, RG
    MOERTEL, CG
    OCONNELL, MJ
    RUBIN, J
    CREAGAN, ET
    [J]. CANCER TREATMENT REPORTS, 1983, 67 (05): : 505 - 506
  • [22] DOXORUBICIN IN COMBINATION WITH VERAPAMIL IN ADVANCED COLORECTAL-CANCER - A PHASE-II TRIAL
    DALMARK, M
    PALS, H
    JOHNSEN, AH
    [J]. ACTA ONCOLOGICA, 1991, 30 (01) : 23 - 26
  • [23] PHASE-II AND PHARMACOKINETIC STUDY OF FOTEMUSTINE IN INOPERABLE COLORECTAL-CANCER
    ROUGIER, P
    CHABOT, GG
    BONNETERRE, J
    TIGAUD, JM
    LUCAS, C
    BAUD, M
    BERILLE, J
    GOUYETTE, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1993, 29A (02) : 288 - 289
  • [24] TOPICALLY APPLIED MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN PATIENTS WITH SKIN-METASTASIZED BREAST-CANCER - A PHASE-II STUDY
    UNGER, C
    HERRMANN, R
    BERDEL, WE
    KLEEBERG, UR
    GATZEMEIER, U
    ILLIGER, HJ
    WANDER, HE
    WESTERHAUSEN, M
    BECHER, R
    BREMER, K
    RIECHE, K
    ESSERS, U
    QUEISSER, W
    HEIDEMANN, E
    FIEBIG, HH
    POSSINGER, K
    JOURDAINMADL, B
    HEIM, ME
    EDLER, L
    [J]. ONKOLOGIE, 1993, 16 (03): : 170 - 173
  • [25] PHASE-II TRIAL OF BISANTRENE IN ADVANCED COLORECTAL-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY
    PERRY, MC
    FORASTIERE, AA
    RICHARDS, F
    WEISS, RB
    ANBAR, D
    [J]. CANCER TREATMENT REPORTS, 1982, 66 (11): : 1997 - 1998
  • [26] PHASE-II TRIAL OF ECHINOMYCIN IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST ONCOLOGY GROUP-STUDY
    BROWN, TD
    GOODMAN, PJ
    FLEMING, TR
    TAYLOR, SA
    MACDONALD, JS
    [J]. INVESTIGATIONAL NEW DRUGS, 1991, 9 (01) : 113 - 114
  • [27] PHASE-II TRIAL OF AMONAFIDE IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST-ONCOLOGY-GROUP-STUDY
    BROWN, TD
    GOODMAN, PJ
    FLEMING, T
    MACDONALD, JS
    CRAIG, JB
    EINSTEIN, AB
    [J]. ANTI-CANCER DRUGS, 1993, 4 (01) : 49 - 50
  • [28] PHASE-II STUDY OF ACNU AS 1ST-LINE TREATMENT IN ADVANCED COLORECTAL-CANCER
    PLANTING, A
    HOFF, A
    VANDERBURG, M
    VERWEIJ, J
    STOTER, G
    [J]. ANNALS OF ONCOLOGY, 1991, 2 (10) : 767 - 768
  • [29] PHASE-II STUDY OF TALLYSOMYCIN-S10B IN PATIENTS WITH ADVANCED COLORECTAL-CANCER
    NICAISE, C
    AJANI, J
    GOUDEAU, P
    ROZENCWEIG, M
    LEVIN, B
    KRAKOFF, I
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 (03) : 221 - 222
  • [30] PHASE-II STUDY OF EPIRUBICIN SEQUENTIAL METHOTREXATE AND 5-FLUOROURACIL FOR ADVANCED COLORECTAL-CANCER
    PYRHONEN, SO
    KOURI, MO
    [J]. EUROPEAN JOURNAL OF CANCER, 1992, 28A (11) : 1828 - 1832
12345